Suppr超能文献

重组因子 XIII A 链的羧基末端截短。转谷氨酰胺酶活性的最小结构要求的表征。

Carboxyl-terminal truncation of recombinant factor XIII A-chains. Characterization of minimum structural requirement for transglutaminase activity.

作者信息

Lai T S, Achyuthan K E, Santiago M A, Greenberg G S

机构信息

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.

出版信息

J Biol Chem. 1994 Oct 7;269(40):24596-601.

PMID:7929131
Abstract

A series of truncation mutants lacking 218, 229, 250, and 269 amino acid residues from the carboxyl terminus of blood coagulation factor XIII A-chains (FXIII A), designated as delta K513, delta A502, delta Y481, and delta K462, respectively, were expressed in Escherichia coli to define the minimum structure required for transglutaminase activity. delta K513 and delta A502 displayed a 3.8-4.7-fold reduction in the Kcat with no change in the Km for the glutamine substrate and a 2-fold increase in the Km of the primary amine substrate. There was no detectable transglutaminase activity for either thrombin-activated delta Y481 or delta K462. The rate of ammonia release of thrombin-activated delta K513 and delta A502 was reduced 6- and 4-fold, respectively, whereas ammonia release was not detected for the delta Y481 and delta 462 mutants. The Kact for calcium ions of the delta K513 mutant was similar to recombinant FXIIIa, whereas, it was increased by approximately 3-fold for the delta A502 mutant. The rate of fibrin gamma-chain dimer formation for the delta K513 and delta A502 mutants was reduced by approximately 19-fold. delta K462 did not bind to fibrin, while all of the other thrombin-cleaved mutants were bound. In conclusion, these results documented that the carboxyl-terminal calcium binding domain (Asp468-Glu495) was important for FXIIIa to adopt the correct conformation to ensure that efficient catalysis occurred.

摘要

一系列分别从凝血因子 XIII A 链(FXIII A)羧基末端缺失 218、229、250 和 269 个氨基酸残基的截短突变体,分别命名为 ΔK513、ΔA502、ΔY481 和 ΔK462,在大肠杆菌中表达,以确定转谷氨酰胺酶活性所需的最小结构。ΔK513 和 ΔA502 的催化常数(Kcat)降低了 3.8 - 4.7 倍,谷氨酰胺底物的米氏常数(Km)不变,伯胺底物的 Km 增加了 2 倍。凝血酶激活的 ΔY481 或 ΔK462 均未检测到转谷氨酰胺酶活性。凝血酶激活的 ΔK513 和 ΔA502 的氨释放速率分别降低了 6 倍和 4 倍,而 ΔY481 和 Δ462 突变体未检测到氨释放。ΔK513 突变体对钙离子的激活常数(Kact)与重组 FXIIIa 相似,而 ΔA502 突变体则增加了约 3 倍。ΔK513 和 ΔA502 突变体的纤维蛋白γ链二聚体形成速率降低了约 19 倍。ΔK462 不与纤维蛋白结合,而所有其他凝血酶切割的突变体均能结合。总之,这些结果证明羧基末端钙结合结构域(Asp468 - Glu495)对于 FXIIIa 采用正确构象以确保有效催化的发生很重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验